Isis Pharmaceuticals, Inc.'s
) shares were up 29.2% shortly after the company presented
impressive data on ISIS-APOCIIIRx at the American Diabetes
The company said that ISIS-APOCIIIRx reduced triglyceride
levels and increased good cholesterol levels in type II diabetes
patients with high triglycerides. Results from a phase II study
showed that patients in the ISIS-APOCIIIRx arm saw an 88%
reduction in apolipoprotein C-III, a 72% reduction in
triglyceride levels and a 40% improvement in good cholesterol
levels (high-density lipoprotein cholesterol (HDL-C)).
Isis Pharma reported improvement in other lipid parameters as
well as several measures of glucose control.
The candidate's safety profile was also good with no
discontinuations, clinically meaningful elevations in liver
enzymes, flu-like symptoms, or major adverse events being
reported. Results from another phase II study evaluating
ISIS-APOCIIIRx in patients with moderate to severe high
triglycerides should be out this summer.
ISIS-APOCIIIRx is one of the most promising candidates in Isis
Pharma's pipeline. The phase II data is encouraging and we look
forward to seeing additional data on the candidate.
Isis Pharma currently carries a Zacks Rank #2 (Buy). We view
Kynamro's Jan 2013 approval in the US as a major milestone for
the company. Kynamro was launched in late Mar 2013 and we expect
investor focus to remain on the product's performance. The
company has made significant progress with its pipeline - Isis
Pharma has several candidates in phase II or phase III
development including five that could reach the market by 2018.
The next 12-18 months should be catalyst filled with the company
expected to report results from several studies.
Other companies that currently look well-positioned include
Aeterna Zentaris Inc.
Protalix BioTherapeutics, Inc.
). All three are Zacks Rank #1 (Strong Buy) stocks.
AETERNA ZENTARS (AEZS): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
ISIS PHARMACEUT (ISIS): Free Stock Analysis
PROTALIX BIOTHR (PLX): Free Stock Analysis
To read this article on Zacks.com click here.